Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Verheij

Showing results (11-20 of 182) with videos related to

Pageof 19
Sort By:
The Lancet. Oncology|July 12, 2016
Adverse event development in clinical oncology trialsIris Walraven, Neil Aaronson, Jan-Jakob Sonke, et al.
The Lancet. Oncology|April 8, 2015
Radiotherapy dose and fractionation for stage III NSCLCJosé Belderbos, Iris Walraven, Judi van Diessen, et al.
International Journal of Radiation Oncology, Biology, Physics|January 31, 2004
Apoptosis-modulating agents in combination with radiotherapy-current status and outlookClaus Belka, Verena Jendrossek, Martin Pruschy, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2014
NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo studyShuraila F Zerp, Conchita Vens, Ben Floot, et al.
Technical Innovations & Patient Support in Radiation Oncology|June 19, 2025
The impact of digital tools and the expected digital transformation in radiotherapy on Dutch radiation therapists (RTTs)Thijs Ackermans, Paul Cremers, Janne Dingemans, et al.
Radiation Research|February 22, 2012
Imaging radiotherapy-induced apoptosisAdriana Haimovitz-Friedman, Tzu-I Jonathan Yang, Tin Htwe Thin, et al.
Clinical and Translational Radiation Oncology|June 25, 2020
Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model systemShuraila F Zerp, Zainab Bibi, Inge Verbrugge, et al.
Cancer Treatment Reviews|February 9, 2007
Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapyStefan R Vink, Wim J van Blitterswijk, Jan H M Schellens, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 16, 2021
Implementation of MR-linac and proton therapy in two radiotherapy departments in The Netherlands: Recommendations based on lessons learnedMaria Jacobs, Linda Kerkmeijer, Dirk de Ruysscher, et al.
Frontiers in Oncology|February 19, 2021
MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?Juliane Hörner-Rieber, Sebastian Klüter, Jürgen Debus, et al.
Pageof 19

Showing results (11-20 of 182) with videos related to

Sort By:
Pageof 19
The Lancet. Oncology|July 12, 2016
Adverse event development in clinical oncology trialsIris Walraven, Neil Aaronson, Jan-Jakob Sonke, et al.
The Lancet. Oncology|April 8, 2015
Radiotherapy dose and fractionation for stage III NSCLCJosé Belderbos, Iris Walraven, Judi van Diessen, et al.
International Journal of Radiation Oncology, Biology, Physics|January 31, 2004
Apoptosis-modulating agents in combination with radiotherapy-current status and outlookClaus Belka, Verena Jendrossek, Martin Pruschy, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2014
NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo studyShuraila F Zerp, Conchita Vens, Ben Floot, et al.
Technical Innovations & Patient Support in Radiation Oncology|June 19, 2025
The impact of digital tools and the expected digital transformation in radiotherapy on Dutch radiation therapists (RTTs)Thijs Ackermans, Paul Cremers, Janne Dingemans, et al.
Radiation Research|February 22, 2012
Imaging radiotherapy-induced apoptosisAdriana Haimovitz-Friedman, Tzu-I Jonathan Yang, Tin Htwe Thin, et al.
Clinical and Translational Radiation Oncology|June 25, 2020
Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model systemShuraila F Zerp, Zainab Bibi, Inge Verbrugge, et al.
Cancer Treatment Reviews|February 9, 2007
Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapyStefan R Vink, Wim J van Blitterswijk, Jan H M Schellens, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 16, 2021
Implementation of MR-linac and proton therapy in two radiotherapy departments in The Netherlands: Recommendations based on lessons learnedMaria Jacobs, Linda Kerkmeijer, Dirk de Ruysscher, et al.
Frontiers in Oncology|February 19, 2021
MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?Juliane Hörner-Rieber, Sebastian Klüter, Jürgen Debus, et al.
Pageof 19